Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macrafol-FA is an oral nutritional supplement formulated as softgel capsules, developed and marketed by TCF Pharmaceuticals. It is a combination product containing ferrous ascorbate, folic acid, methylcobalamin, and adenosylcobalamin. It is primarily indicated for the management of anemia and nutritional support in gynecological care, including pregnancy. Ferrous ascorbate serves as a highly bioavailable source of iron to replenish hemoglobin levels. Folic acid (vitamin B9) is essential for DNA synthesis and red blood cell production, helping to prevent neural tube defects during pregnancy. Methylcobalamin and adenosylcobalamin are active coenzyme forms of vitamin B12 that support neurological function, myelin sheath maintenance, and mitochondrial energy metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Macrafol-FA.